Article
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer.
Science advances - 29 Mar 2024
Pillai Ray, LeBoeuf Sarah E, Hao Yuan, New Connie, Blum Jenna L E, Rashidfarrokhi Ali, Huang Shih Ming, Bahamon Christian, Wu Warren L, Karadal-Ferrena Burcu, Herrera Alberto, Ivanova Ellie, Cross Michael, Bossowski Jozef P, Ding Hongyu, Hayashi Makiko, Rajalingam Sahith, Karakousi Triantafyllia, Sayin Volkan I, Khanna Kamal M, Wong Kwok-Kin, Wild Robert, Tsirigos Aristotelis, Poirier John T, Rudin Charles M, Davidson Shawn M, Koralov Sergei B, Papagiannakopoulos Thales
Abstract excerpt
Loss-of-function mutations in KEAP1 frequently occur in lung cancer and are associated with poor prognosis and resistance to standard of care treatment, highlighting the need for the development of targeted therapies. We previously showed that KEAP1 mutant tumors consume glutamine to support the metabolic rewiring associated with NRF2-dependent antioxidant production. Here, using preclinical patient-derived...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.